Epizyme Inc. (NASDAQ:EPZM) has earned an average rating of “Buy” from the ten ratings firms that are currently covering the company. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $22.00.
A number of research analysts recently issued reports on EPZM shares. HC Wainwright reiterated a “buy” rating on shares of Epizyme in a research note on Tuesday, August 9th. Cowen and Company restated a “buy” rating on shares of Epizyme in a research report on Monday, June 20th. Mizuho restated a “buy” rating and issued a $18.00 price target on shares of Epizyme in a research report on Monday, June 20th. Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Monday, July 11th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $26.00 price target on shares of Epizyme in a research report on Monday, June 20th.
In other news, insider Robert A. Copeland sold 4,000 shares of the firm’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $10.37, for a total transaction of $41,480.00. Following the completion of the transaction, the insider now directly owns 35,538 shares of the company’s stock, valued at approximately $368,529.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 25.40% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd purchased a new position in shares of Epizyme during the second quarter valued at about $104,000. HBK Investments L P purchased a new position in shares of Epizyme during the first quarter valued at about $149,000. State Board of Administration of Florida Retirement System increased its position in shares of Epizyme by 15.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 15,347 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 2,102 shares in the last quarter. American International Group Inc. increased its position in shares of Epizyme by 36.2% in the second quarter. American International Group Inc. now owns 23,167 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 6,155 shares in the last quarter. Finally, Woodstock Corp purchased a new position in shares of Epizyme during the second quarter valued at about $282,000. 80.79% of the stock is owned by hedge funds and other institutional investors.
Shares of Epizyme (NASDAQ:EPZM) opened at 8.90 on Tuesday. Epizyme has a 1-year low of $7.02 and a 1-year high of $18.29. The company’s 50-day moving average is $8.80 and its 200 day moving average is $10.12. The firm’s market cap is $515.81 million.
Epizyme (NASDAQ:EPZM) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.03. Epizyme had a negative net margin of 5,174.49% and a negative return on equity of 43.05%. On average, equities research analysts expect that Epizyme will post ($2.20) EPS for the current fiscal year.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.